FIELD: medicine.
SUBSTANCE: autophagy inhibitor based on thioxanthone is used to manufacture a medicament for cancer treatment in combination with an autophagy-causing compound. A pharmaceutical composition and a pharmaceutical kit for cancer treatment containing an autophagy inhibitor based on thioxanthone and an autophagic compound are also provided.
EFFECT: increased anticancer activity of therapy due to decreased cell viability and increased apoptosis.
8 cl, 26 dwg, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BIFUNCTIONAL COMPOSITIONS FOR CANCER TREATMENT | 2019 |
|
RU2764175C1 |
| NOVEL APPROACH TO CANCER TREATMENT USING IMMUNOMODULATION | 2016 |
|
RU2817047C2 |
| NEW APPROACH TO TREATING CANCER WITH APPLICATION OF IMMUNOMODULATION | 2016 |
|
RU2711380C2 |
| COMBINED THERAPY WITH EZH2 INHIBITOR | 2018 |
|
RU2754131C1 |
| 5-[[4-[[MORPHOLIN-2-YL]METHYLAMINO]-5-(TRIFLUOROMETHYL)-2-PYRIDYL]AMINO]PYRAZINE-2-CARBONITRILE, THERAPEUTIC USES THEREOF | 2013 |
|
RU2659786C2 |
| DOSAGE FORMS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND THEIR APPLICATION | 2011 |
|
RU2609833C2 |
| COMBINED THERAPY PAC-1 | 2016 |
|
RU2720509C2 |
| METHOD FOR IDENTIFYING COMPOUNDS FOR TREATING CANCER | 2010 |
|
RU2575828C2 |
| MUTANT SELECTIVITY AND COMBINATIONS OF A PHOSPHOINOSITIDE-3-KINASE INHIBITOR COMPOUND AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | 2013 |
|
RU2665949C2 |
| PROCASPASE 3 ACTIVATION BY COMBINATION THERAPY | 2013 |
|
RU2659936C2 |
